Insulin purchasers submitted a request to a federal judge in New Jersey on May 26 regarding a proposed settlement for a class action lawsuit against Eli Lilly & Co., claiming that the company inflated the medication’s price.
As per the proposed agreement, the pharmaceutical company would offer a payment of $13.5 million and establish a cap on the price of insulin.
After six years of litigation, Insulin buyers and Eli Lilly have agreed to a proposed class action settlement. The settlement allows eligible patients to purchase Eli Lilly insulin medications sold under the Humalog, Humulin and Basaglar names for a maximum of $35 out of pocket each month, according to the settlement motion.
Read more: Eli Lilly To Cut Insulin Prices By 70%, Cap Customers’ Costs
According to the motion for preliminary approval of the class action settlement, the insulin price cap would be ensured for a minimum of four years.
If approved, individuals who bought Eli Lilly insulin products covered by the settlement may receive cash payments from the $13.5 million class action settlement fund.
“The settlement provides no reversion to Lilly and completely freezes the out-of-pocket insulin expenses for covered insulin products for the settlement class members for four years, a very substantial concession in an era where drug prices are skyrocketing and inflation generally is a significant concern,” the plaintiffs say in their motion.
Featured News
DOJ and FTC Introduce Website for Reporting Anti-Competitive Healthcare Practices
Apr 18, 2024 by
CPI
US Congress Advances Legislation to Compel TikTok Sale
Apr 18, 2024 by
CPI
UK Financial Sector Advocates Enhanced Regulatory Accountability
Apr 18, 2024 by
CPI
Google and All 50 States Defend $700 Million Consumer Settlement
Apr 18, 2024 by
CPI
Colorado Enacts First Law to Protect Consumer Brainwave Data
Apr 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI